ADMA BIOLOGICS, INC. Stockholders Equity

Quick Answer

ADMA BIOLOGICS, INC. reported Stockholders Equity of $477.32 million for fiscal year 2025.

ADMA BIOLOGICS, INC. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $477.32M +36.8%
2024 $349.02M +158.1%
2023 $135.21M -11.0%
2022 $151.97M +7.7%
2021 $141.17M +60.0%
2020 $88.25M +236.9%
2019 $26.19M +32.5%
2018 $19.77M -51.0%
2017 $40.33M +1004.9%
2016 -$4.46M -642.9%
2015 $821.0K -86.3%
2014 $6.01M -72.1%
2013 $21.57M +128.9%
2012 $9.42M +2342.5%
2011 $385.8K +109.8%
2010 -$3.93M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $431.19M +85.9% +8.2%
June 30, 2025 $398.32M +111.6% +6.7%
March 31, 2025 $373.42M +142.9% +7.0%
December 31, 2024 $349.02M +158.1% +50.5%
September 30, 2024 $231.89M +53.1% +23.2%
June 30, 2024 $188.27M +28.3% +22.5%
March 31, 2024 $153.71M +5.5% +13.7%
December 31, 2023 $135.21M -11.0% -10.7%
  • ADMA BIOLOGICS, INC. showed an increase of +36.8% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2010–2025 period, ADMA BIOLOGICS, INC.’s stockholders equity has grown by 12255.8% (from -$3.93 million to $477.32 million).
  • The most recent figure is from ADMA BIOLOGICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment